DDX17在非小细胞肺癌中的表达及临床意义

Expression of DDX17 in non-small cell lung cancer and its clinical significance

目的：探索DDX17在非小细胞肺癌及癌旁组织中的表达差异及其临床意义。方法：采用免疫组织化学法检测非小细胞肺癌患者肿瘤组织及相应癌旁组织中DDX17的表达情况。分析DDX17表达与患者临床病理特征之间的相关性,以及DDX17对患者生存预后的预测价值。结果：DDX17在非小细胞肺癌组织中的表达量明显高于癌旁组织,其表达高低与肿瘤大小、淋巴结转移状态和病理分期显著相关。随着肺癌分期提高,DDX17的表达也增加。DDX17高表达和低表达患者的中位总生存时间分别为16个月和38个月（HR3.15,95%CI 2.036~4.874）,差异具有统计学意义（P〈0.001）。单因素和多因素分析显示,DDX17的表达、病理分期、淋巴结转移状态和是否接受辅助化疗是非小细胞肺癌患者独立的生存预后不良指标。结论：DDX17高表达于非小细胞肺癌组织,是独立的预后预测因子。

Objective： To study the expression of DDX17 in non- small cell lung cancer（ NSCLC） tissues and its clinical significance. Methods： Immunohistochemistry was performed to detect the expression of DDX17 in NSCLC tissues and the corresponding adjacent tissues. The correlation between DDX17 expression and clinicpathological characteristics was analyzed. The prognostic significance of DDX17 was explored by survival analysis. Results： The expression of DDX17 in NSCLC tissues was significantly higher compared with their adjacent counterparts. DDX17 expression was positively correlated with tumor size,nodal status and pathological stage. The expression of DDX17 increased with the stage of NSCLC. The median overall survival of NSCLC patients with high and low expression of DDX17 was16 and 38 months respectively（ HR 3. 15,95% CI 2. 036 4. 874,P 0. 001）. Univariate and multi- variate analysis suggested that DDX17,pathological stage,nodal status and previous adjuvant chemotherapy were independent prognostic factors for overall survival of NSCLC patients. Conclusion： The expression of DDX17 was significantly higher in NSCLC tissues than its expression in adjacent tissues. DDX17 is an independent prognostic factor for NSCLC patients.